EP1578996A4 - Zusammensetzungen und verfahren für die tumor-diagnose und behandlung - Google Patents

Zusammensetzungen und verfahren für die tumor-diagnose und behandlung

Info

Publication number
EP1578996A4
EP1578996A4 EP03813488A EP03813488A EP1578996A4 EP 1578996 A4 EP1578996 A4 EP 1578996A4 EP 03813488 A EP03813488 A EP 03813488A EP 03813488 A EP03813488 A EP 03813488A EP 1578996 A4 EP1578996 A4 EP 1578996A4
Authority
EP
European Patent Office
Prior art keywords
diagnosing
compositions
methods
treating tumors
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813488A
Other languages
English (en)
French (fr)
Other versions
EP1578996A2 (de
Inventor
Thomas D Wu
Yan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP1578996A2 publication Critical patent/EP1578996A2/de
Publication of EP1578996A4 publication Critical patent/EP1578996A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03813488A 2002-10-18 2003-10-15 Zusammensetzungen und verfahren für die tumor-diagnose und behandlung Withdrawn EP1578996A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41898802P 2002-10-18 2002-10-18
US418988P 2002-10-18
PCT/US2003/029126 WO2004060270A2 (en) 2002-10-18 2003-10-15 Compositions and methods for the diagnosis and treatment of tumor

Publications (2)

Publication Number Publication Date
EP1578996A2 EP1578996A2 (de) 2005-09-28
EP1578996A4 true EP1578996A4 (de) 2007-12-19

Family

ID=32712943

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813488A Withdrawn EP1578996A4 (de) 2002-10-18 2003-10-15 Zusammensetzungen und verfahren für die tumor-diagnose und behandlung

Country Status (5)

Country Link
EP (1) EP1578996A4 (de)
JP (1) JP2006516192A (de)
AU (1) AU2003303144A1 (de)
CA (1) CA2503043A1 (de)
WO (1) WO2004060270A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
AU2003226131A1 (en) 2002-03-28 2003-10-13 Bristol-Myers Squibb Company Novel human cell surface protein with immunoglobulin folds, bgs-19
WO2003091402A2 (en) * 2002-04-23 2003-11-06 University Of Georgia Research Foundation, Inc. N-ACETYLGLUCOSAMINYLTRANSFERASE Vb CODING SEQUENCE, RECOMBINANT CELLS AND METHODS
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP2005230011A (ja) * 2004-02-20 2005-09-02 Samsung Electronics Co Ltd 乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
EP2319925B1 (de) 2004-08-16 2018-07-25 Quark Pharmaceuticals, Inc. Therapeutische Verwendungen von RTP801-Hemmern
GB0422211D0 (en) * 2004-10-06 2004-11-03 Randox Lab Ltd Method
US20080145369A1 (en) * 2004-10-13 2008-06-19 Ginette Serrero Autocrine Growth Factor Receptors and Methods
JP2007008844A (ja) * 2005-06-29 2007-01-18 Nippon Flour Mills Co Ltd セプチン２タンパク質と特異的に反応するモノクローナル抗体、それを産生するハイブリドーマ、癌の検出方法及び癌の検出用キット
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
CN103424541B (zh) * 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
WO2008148072A2 (en) * 2007-05-24 2008-12-04 The Brigham And Women's Hospital, Inc. Disease-associated genetic variations and methods for obtaining and using same
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
EP2334790A1 (de) * 2008-08-27 2011-06-22 Oncotherapy Science, Inc. Gen ttll4 in verbindung mit pankreaskarzinom
SMT202300421T1 (it) 2009-02-20 2024-01-10 Astellas Pharma Inc Metodi e composizioni per la diagnosi e il trattamento del cancro
DK3305813T3 (da) 2009-11-11 2020-04-20 Astellas Pharma Inc Antistoffer, der er specifikke for claudin 6 (cldn6)
WO2011150400A1 (en) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Nuclear scaffold protein stip/tfip11 target for cancer therapy
EP2404936A1 (de) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Krebstherapie mittels CLDN6-zielgerichteter Antikörper im lebenden Organismus
ES2989943T3 (es) 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
DK2928921T3 (da) 2012-12-05 2021-04-19 Novartis Ag Sammensætninger og fremgangsmåder til antistoffer målrettet epo
EP3388834B1 (de) * 2013-03-15 2020-04-15 Translate Bio, Inc. Synergistische verbesserung der abgabe von nukleinsäuren durch gemischte formulierungen
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MX2019014027A (es) 2017-05-24 2020-08-03 Thoeris Gmbh Uso de glutamina sintetasa para tratar hiperamonemia.
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
IL281470B2 (en) 2018-09-28 2025-08-01 Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
JP7766904B2 (ja) * 2021-06-04 2025-11-11 地方独立行政法人東京都健康長寿医療センター 前立腺がん治療用医薬組成物
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420140A1 (en) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20040014392A (ko) * 2000-08-24 2004-02-14 제넨테크, 인크. 종양의 진단 및 치료용 조성물 및 방법
AU8678501A (en) * 2000-08-24 2002-03-04 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL/GENBANK/DDBJ 13 June 2001 (2001-06-13), STRAUSBERG, R.L. ET AL: "Homo sapiens papillary renal cell carcinoma", XP002446467, retrieved from EBI Database accession no. BC010450 *
WETERMAN MARIAN A J ET AL: "Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1) (p11;q21)-positive papillary renal cell carcinomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 26, 1996, pages 15294 - 15298, XP002446464, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1578996A2 (de) 2005-09-28
WO2004060270A8 (en) 2005-07-14
WO2004060270A2 (en) 2004-07-22
AU2003303144A1 (en) 2004-07-29
CA2503043A1 (en) 2004-07-22
JP2006516192A (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
EP1578996A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
EP1571968A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP1578371A4 (de) Zusammensetzungen und verfahren für die tumor-diagnose und behandlung
EP1572091A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
EP1663259A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP1696877A4 (de) Verfahren zur schmerzbehandlung
EP1701725A4 (de) Verfahren und zusammensetzungen
EP1796666A4 (de) Verfahren und zusammensetzungen zur behandlung von hyperlipidämie
EP1585482A4 (de) Neue zusammensetzungen und verfahren zur behandlung von psoriasis
EP1639090A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
EP1961065A4 (de) Zusammensetzungen und verfahren zur diagnostizierung und behandlung von krebs
EP1583504A4 (de) Verfahren und zusammensetzungen für diagnose, prognose und behandlung von krebs
EP1814909A4 (de) Verwendung von aimp2dx2 zur diagnose und behandlung von krebs
EP1755391A4 (de) Verfahren und zusammensetzungen zur behandlung von nervenleiden
IL176259A0 (en) Compositions and methods for treating diabetes
EP1575580A4 (de) Verfahren zur behandlung von karzinomen
EP1660009A4 (de) Verfahren zur behandlung von endometriose
EP1576110A4 (de) Zellwanderungshemmende zusammensetzungen sowie verfahren und zusammensetzungen zur krebsbehandlung
EP1677735A4 (de) Verfahren und zusammensetzungen zur modulierung der adipozyten-funktion
NO20054711D0 (no) Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer
EP1575571A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
NO20040058L (no) Innholdslesende apparat
EP1648474A4 (de) Verfahren und pharmazeutische zusammensetzungen zur wundheilung
EP1442062A4 (de) Verfahren zur behandlung von karzinomen
EP1572118A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs mit 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050425

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHOU, YAN

Inventor name: WU, THOMAS, D.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENENTECH, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20071119

17Q First examination report despatched

Effective date: 20080728

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090210